Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PH94B in the Treatment of Adjustment Disorder With Anxiety

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04404192
Recruitment Status : Not yet recruiting
First Posted : May 27, 2020
Last Update Posted : May 27, 2020
Sponsor:
Information provided by (Responsible Party):
VistaGen Therapeutics, Inc.

Brief Summary:
This open-label clinical study is designed to evaluate the efficacy, safety and tolerability of the PRN (on demand) administration of PH94B neuroactive nasal spray as a treatment of Adjustment Disorder with Anxiety symptoms in adults. Subject participation in the study will last a total of from eight (8) to fifteen (15) weeks, depending on the duration of the screening period. Upon signing an IRB-approved informed consent form (ICF), all subjects will complete Visit 1 and enter a screening period lasting between fourteen (14) and forty-five (45) days to determine eligibility and washout any contraindicated anti-anxiety medications. If subjects meet all eligibility criteria at the end of the screening period, subjects will complete Visit 2, the baseline visit, and will then commence four (4) weeks of open-label treatment with PH94B on an as-needed basis. During the four (4)-week treatment period, subjects will complete weekly study visits (Visits 3-6). Two (2) weeks following completion of Visit 6, subjects will complete a final safety follow-up visit (Visit 7).

Condition or disease Intervention/treatment Phase
Adjustment Disorder With Anxious Mood Drug: PH94B Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: PH94B
Intranasal spray 3.2 micrograms up to four times a day as needed for anxiety for 14 days.
Drug: PH94B
Intranasal administration up to 4 times a day as needed for anxiety
Other Name: Aloradine




Primary Outcome Measures :
  1. Hamilton Anxiety Scale [ Time Frame: 14 days ]
    Questionnaire on anxiety symptoms - change from baseline


Secondary Outcome Measures :
  1. Sheehan Disability Scale [ Time Frame: 14 days ]
    Questionnaire on functioning - change from baseline

  2. Adjustment Disorder New Module (ADNM) [ Time Frame: 14 days ]
    Questionnaire on worrying etc. - change from baseline

  3. Clinical Global Impression - Improvement rating (CGI-I) [ Time Frame: 14 days ]
    Clinical impression of improvement - change from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female adults, 18 through 75 years of age, inclusive.
  2. Current diagnosis of Adjustment Disorder with Anxiety (AjDA) as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
  3. Clinician-rated Hamilton Anxiety Rating Scale (HAM-A) score ≥20 at both Screening (Visit 1) and Baseline (Visit 2) visits.
  4. Clinician-rated Hamilton Depression Rating Scale (HAM-D17) total score <18 at both Screening and Baseline visits.
  5. Clinical Global Impression - Severity Scale (CGI-S) score ≥4 at both Screening and Baseline visits.
  6. Women of child-bearing-potential must be able to commit to the consistent and correct use of an effective method of birth control throughout the study, and must also have a negative urine pregnancy test result at both Screening and Baseline visits, prior to study drug administration. Effective methods of contraception include: condoms with spermicide; diaphragm with spermicide; hormonal contraceptive agents (oral, transdermal; or injectable) or implantable contraceptive devices.

Exclusion Criteria:

  1. Any history of schizophrenia or schizoaffective disorder.
  2. Any other current Axis I disorder, including, but not limited to, Major Depressive Disorder (MDD), Bipolar disorder (BD), Post-Traumatic Stress Disorder (PTSD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), which is in poor control and the primary focus of treatment.
  3. A primary diagnosis of social anxiety disorder (SAD) with a score >60 on the Liebowitz Social Anxiety Disorder Scale.
  4. Subjects who meet criteria for moderate or severe alcohol or substance use disorder within the one (1) year prior to study entry.
  5. In the opinion of the Investigator, the subject has a significant risk for suicidal behavior during the course of their participation in the study, or:

    1. At Screening: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C SSRS) with reference to a six (6)-month period prior to screening; or
    2. At Screening: the subject has had one (1) or more suicidal attempts with reference to a teo (2)-year period prior to screening; or
    3. At Baseline: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to screening; or
    4. Considered to be an imminent danger to themself or others.
  6. Currently testing positive for SARS-CoV-2 or currently suffering from COVID-19
  7. Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, or nasal septum perforation that may have damaged the nasal chemosensory epithelium.
  8. An acute or chronic condition, including an infectious illness, uncontrolled seasonal allergies at the time of the study, or significant nasal congestion that potentially could affect drug delivery to the nasal chemosensory epithelium. The Investigator may allow concomitant use of over-the-counter (OTC) nasal decongestants as needed, since there is no interaction between these and PH94B (PH94B PER 01A).
  9. Concomitant use of any anxiolytic, such as a benzodiazepine or buspirone, during the study and within thirty (30) days prior to study entry.
  10. Concomitant use of any OTC, prescription product, or herbal preparation such as cannabidiol, for treatment of the symptoms of anxiety during the study and within thirty (30) days prior to study entry.
  11. Women who have a positive urine pregnancy test prior to study drug administration.
  12. Subjects with clinically significant abnormalities in hematology, blood chemistry, urinalysis, electrocardiogram (ECG), or physical examination identified at Screening or Baseline that in the clinical judgment of the Investigator, could place the subject at undue risk, interfere with study participation, or confound the results of the study.
  13. Subjects with a positive urine drug screen at either Screening or Baseline.
  14. Any current clinically significant and/or uncontrolled medical condition that, in the clinical judgment of the Investigator, could place the subject at undue risk, interfere with study participation, or confound the results of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04404192


Contacts
Layout table for location contacts
Contact: Matt Turzilli 212-595-5012 mturzilli@medicalresearchnetwork.com

Locations
Layout table for location information
United States, New York
The Medical Research Network
New York, New York, United States, 10128
Contact: Ann Draine    212-595-5012    Information@MedicalResearchNetwork.com   
Principal Investigator: Michael Liebowitz, MD         
Sponsors and Collaborators
VistaGen Therapeutics, Inc.
Layout table for additonal information
Responsible Party: VistaGen Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04404192    
Other Study ID Numbers: PH94B-CL-029
First Posted: May 27, 2020    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Adjustment Disorders
Trauma and Stressor Related Disorders
Mental Disorders